Why the study?
Does low-dose or very-low-dose rivaroxaban reduce clinically significant bleeding compared to standard vitamin K antagonist therapy in participants with atrial fibrillation undergoing PCI with stent placement?
Does low-dose or very-low-dose rivaroxaban reduce clinically significant bleeding compared to standard vitamin K antagonist therapy in participants with atrial fibrillation undergoing PCI with stent placement?
In patients with atrial fibrillation undergoing PCI, rivaroxaban-based antithrombotic regimens reduce clinically significant bleeding compared to standard vitamin K antagonist plus DAPT.
No takes yet. Share an insight, caveat, or question.
Supports rivaroxaban regimens to lower bleeding versus VKA plus DAPT in AF-PCI; confirms modified therapy benefits in randomized data.
Gibson et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: